Search by Drug Name or NDC

    NDC 50419-0393-03 VITRAKVI 20 mg/mL Details

    VITRAKVI 20 mg/mL

    VITRAKVI is a OROPHARYNGEAL SOLUTION, CONCENTRATE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bayer HealthCare Pharmaceuticals Inc.. The primary component is LAROTRECTINIB.

    Product Information

    NDC 50419-0393
    Product ID 50419-393_3e340753-c526-4748-9e8a-d99e3511d7ef
    Associated GPIs
    GCN Sequence Number 079308
    GCN Sequence Number Description larotrectinib sulfate SOLUTION 20 MG/ML ORAL
    HIC3 V1Q
    HIC3 Description ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS
    GCN 45789
    HICL Sequence Number 045494
    HICL Sequence Number Description LAROTRECTINIB SULFATE
    Brand/Generic Brand
    Proprietary Name VITRAKVI
    Proprietary Name Suffix n/a
    Non-Proprietary Name LAROTRECTINIB
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form SOLUTION, CONCENTRATE
    Route OROPHARYNGEAL
    Active Ingredient Strength 20
    Active Ingredient Units mg/mL
    Substance Name LAROTRECTINIB
    Labeler Name Bayer HealthCare Pharmaceuticals Inc.
    Pharmaceutical Class Kinase Inhibitor [EPC], Tropomyosin Receptor Kinases Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA211710
    Listing Certified Through 2024-12-31

    Package

    NDC 50419-0393-03 (50419039303)

    NDC Package Code 50419-393-03
    Billing NDC 50419039303
    Package 2 BOTTLE in 1 CARTON (50419-393-03) / 50 mL in 1 BOTTLE (50419-393-02)
    Marketing Start Date 2022-12-06
    NDC Exclude Flag N
    Pricing Information N/A